Overall, 57% of participants had evidence on PET/MRI of inflammation affecting the heart or lungs.
Plaque growth can lead to a higher risk of heart attack, stroke, and other life-threatening cardiovascular events for as long as 1 year.
Post-exertional malaise, or exercise intolerance, was seen in 36% of those with long COVID.
Get weekly COVD-19 updates in your inbox.
Catch the latest episode!
Top COVID FAQs
By CIDRAP & other experts
Read all 7 reports
Standard, symptom-specific international disease codes lack sensitivity and have poor negative predictive value (NPV) for characteristic COVID-19 symptoms, which could skew conclusions derived from them, a cohort study published today in JAMA Network Open shows.
The southern half of the country continues to report the highest death tolls, which nationally may be higher than thought, based on new excess death estimates.
However, a top WHO official warned that calm waters doesn't mean the storm is over, and most of the world is still susceptible to the easily spreading virus.
A case report today in the Centers for Disease Control and Prevention's (CDC's) Morbidity and Mortality Weekly Report describes three cases of multidrug-resistant tuberculosis (MDR-TB) among workers at an Ohio food-processing facility.
The summer decline in social distancing has triggered a spike in bar and restaurant outbreaks, as colleges brace for spread on campuses when students return.
In another development, China reported an infection in a patient who was sick 6 months ago, stoking worries about waning immunity.
New data from a phase 1/2 clinical trial of a vaccine candidate being developed by Pfizer and German biopharmaceutical company BioNTech show the vaccine produced a robust immune response and was tolerable in healthy adults. The results appeared today in Nature.
Health risks to student-athletes led to the decision, and in other developments, nursing homes warned of rising infections and took steps to tighten restrictions.
The National Institute of Allergy and Infectious Diseases (NIAID) yesterday announced that it is enrolling participants for two phase 3 trials of two different monoclonal antibody treatments for COVID-19.
Meanwhile, experts warn that a window of opportunity to control the virus is short, ahead of a likely new COVID-19 surge in the fall.
